000			02192nas a22003615i 4500
001			2365-421X
003			DE-He213
005			20180511105626.0
007			cr nn 008mamaa
008			150810s||||||||gw uu poo|||||| b|EN |d
022			_a2365-421X
024	7		_a41181 _2local
210	1	0	_aEJNMMI radiopharm. chem.
245	1	0	_aEJNMMI Radiopharmacy and Chemistry _h[electronic resource] / _cedited by Philip H. Elsinga.
264		1	_aCham : _bSpringer International Publishing : _bImprint: Springer.
300			_bonline resource.
520			_aEJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. In addition, the journal provides insight in novel concepts of imaging or radionuclide based therapeutic agent applications of relevance for the whole molecular imaging community. The journal reports original research articles, review papers, guidelines on application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in from of guidelines or position papers.
650		0	_aMedicine.
650		0	_aMolecular biology.
650		0	_aNuclear chemistry.
650		0	_aRadiology.
650		0	_aNuclear medicine.
650		0	_aPharmacotherapy.
650	1	4	_aMedicine & Public Health.
650	2	4	_aNuclear Medicine.
650	2	4	_aImaging / Radiology.
650	2	4	_aNuclear Chemistry.
650	2	4	_aPharmacotherapy.
650	2	4	_aMolecular Medicine.
700	1		_aElsinga, Philip H. _eeditor.
710	2		_aSpringerLink (Online service)
856	4	0	_uhttp://link.springer.com/journal/41181 _zOpen Access
999			_c189872 _d189872